Apalutamide in Metastatic Castration-Sensitive Prostate Cancer (mCSPC): A Case-Based Discussion
Release Date: 05/31/2024
Urology Spotlight Series: Andrology/Men’s Health
AUANews Inside Tract
Developed by the Medical Student Membership Workgroup, the Urology Spotlight Series educates medical students about a particular subspecialty within urology, including common cases and procedures. In this episode, Daniela Orozco-Rendon, medical student at Geisel School of Medicine at Dartmouth, is joined by Dr. Mohit Khera, Professor of Urology and F. Brantley Scott Chair in Urology at Baylor College of Medicine, for a discussion on the field of Andrology/Men’s Health.
info_outline
AUA Census Trends: Why Urologists are Choosing Fellowships
AUANews Inside Tract
In this episode, Dr. Amanda North, Chief of Pediatric Urology at Children's Hospital at Montefiore Einstein, joins Dr. Susan MacDonald, Program Director at Penn State, for a deep dive into fellowship training trends in urology. Using AUA census data, they explore generational shifts, gender disparities and evolving motivations for pursuing fellowships. From the growing percentage of women in the field to the increasing complexity of urologic care, they discuss how patient expectations, academic aspirations and practice models are reshaping the specialty. The 2025 AUA Census is now open. Visit...
info_outline
Urology Spotlight Series: Genitourinary Reconstruction
AUANews Inside Tract
Developed by the Medical Student Membership Workgroup, the Urology Spotlight Series educates medical students about a particular subspecialty within urology, including common cases and procedures. In this episode, medical student, Jake Ratanawong, is joined by Dr. Sean Elliott, Professor and Director of Reconstructive Urology at the University of Minnesota, for a discussion on the field of Genitourinary Reconstruction.
info_outline
Navigating the Urology Team: The APP - Physician Dynamic
AUANews Inside Tract
In the fast-paced world of urology, collaboration is key to delivering optimal patient care. Navigating the Urology Team: The APP-Physician Dynamic explores the crucial partnership between Advanced Practice Providers (APPs) and Physicians. This insightful guide delves into how these two roles complement each other, fostering teamwork, enhancing patient outcomes and streamlining clinical workflows. Whether you are a physician or an APP, understanding the unique strengths each brings to the table is vital for building an efficient, patient-centered team.
info_outline
Legislating Urology: The AUA & Advocacy Efforts
AUANews Inside Tract
Join Dr. Andrew Harris and the AUA's Vice President of Legislative and Political Affairs, Brad Stine, as they talk about urologic advocacy, the AUA Summit and how the AUA is involved in legislative affairs.
info_outline
Advancing Prostate Cancer Diagnosis with High-Quality Prostate MR Images
AUANews Inside Tract
Join Dr. Matt Nielsen, Chair of AUA’s Science and Quality Council and Chair of the Department of Urology at University of North Carolina Chapel Hill as he speaks with Dr. Andrei Purysko, Section Head of Abdominal Imaging at the Cleveland Clinic and Physician Leader of the American College of Radiology’s Prostate MR Image Quality Improvement Collaborative, on improving the diagnosis of clinically significant prostate cancer with the use of high-quality prostate MR images. For additional information, please visit AUAnet.org/QISummit.
info_outline
Voices: Health Equity and the Annual Urology Advocacy Summit
AUANews Inside Tract
Today’s podcast episode is part of the “Voices” series and is brought to you by the Diversity, Equity & Inclusion Committee. Join Dr. Michael Davis, the AUA’s’ Gallagher Scholar, as he talks with the AUA’s Public Policy Council Chair, Dr. Mark Edney, about the 8th Annual Urology Summit in Washington, DC, from March 3-5 and how all of their work ties into health equity.
info_outline
Voices: The Power of Presence - A Chat With Dr. Jennifer Miles-Thomas
AUANews Inside Tract
Today’s podcast episode is part of the “Voices” series and is brought to you by the Diversity, Equity & Inclusion Committee. Join Dr. Gjanje Smith-Mathus, a female pelvic medicine and reconstructive surgeon at WakeMed and the founder of the Susu Health Foundation, as she talks with Dr. Jennifer Miles-Thomas, Vice Chair of Integration and Innovation at the Northwestern Medicine Department of Urology and the AUA’s treasurer-elect, about her journey to making AUA history as the first woman, and woman of color, on the Board of Directors, and the importance of representation.
info_outline
Diagnostic Excellence in Urology Care
AUANews Inside Tract
Diagnostic excellence is a concept that has emerged as a model to support the delivery of high-quality, effective, patient-centered care. In this episode, Drs. Nielsen and Friedlander define diagnostic excellence, provide examples of diagnostic excellence in urology, note some of the challenges related to the diagnostic process for urology, and discuss some of the ways that the AUA is planning to help enhance diagnostic excellence going forward. Speakers: Host - Karen Johnson, Director, Quality and Measurement Matt Nielsen, MD, MS, FACS Dave Friedlander, MD, MPH
info_outline
Voices: Creating a Lasting Impact Worldwide With Humanitarianism
AUANews Inside Tract
Today’s podcast episode is part of the “Voices” series and is brought to you by the Diversity, Equity & Inclusion Committee. Join Dr. Kymora Scotland, Assistant Professor and Director of Endourology Research at UCLA Health, the AUA’s most recent Rising Star in Urology and a 2023 recipient of the Humanitarian Grant Program, as she talks with Dr. Ian Metzler, a urologist at OHSU Healthcare and a 2022 recipient of the Humanitarian Grant Program, about their projects and how they are making a lasting impact with their humanitarianism.
info_outlineThis podcast “Apalutamide in Metastatic Castration-Sensitive Prostate Cancer (mCSPC): A Case-Based Discussion” was originally presented as an AUA newsworthy webinar and contains data regarding the clinical efficacy and safety of apalutamide. It is presented on behalf of Janssen and is not certified for CME; speakers were compensated. For full details, see the video webinar here.
TITAN, a Phase 3 double-blind study, randomized patients with metastatic castration-sensitive prostate cancer (mCSPC) to apalutamide (Apa; 240 mg oral once daily) + androgen deprivation therapy (ADT; n=525) or placebo + ADT (n=527).1,2 All patients received a concomitant gonadotropin-releasing hormone analog or had prior bilateral orchiectomy.3 Patients who received prior treatment for localized disease or received but did not progress on docetaxel were permitted. Dual primary endpoints were radiographic progression-free survival and overall survival (OS).1,2
At primary analysis (median follow-up: 22.7 months), Apa + ADT reduced the risk of radiographic progression or death by 52% vs placebo + ADT (HR: 0.48; 95% CI: 0.39–0.60). Apa + ADT also reduced the risk of death by 33% vs placebo + ADT (HR: 0.67; 95% CI: 0.51–0.89).1 At primary analysis cutoff, TITAN was unblinded and 39.5% of patients who received placebo + ADT crossed over to receive Apa + ADT; these patients were analyzed as part of the placebo + ADT population in the intent-to-treat analyses. The IPCW log-rank test was performed to account for crossover and showed a 48% reduction in the risk of death for Apa + ADT vs placebo + ADT (HR: 0.52; 95% CI: 0.42–0.64). At final analysis (median follow-up: 44.0 months), Apa + ADT reduced the risk of death by 35% vs placebo + ADT (median OS: NE vs 52.2 months; HR: 0.65; 95% CI: 0.53–0.79).
In a prespecified subgroup analysis, Apa + ADT improved OS vs placebo + ADT, regardless of disease volume. In patients with high-volume disease, Apa + ADT reduced the risk of death by 30% vs placebo + ADT (HR: 0.70; 95% CI: 0.56–0.88); for low-volume disease, Apa + ADT reduced the risk of death by 48% vs placebo + ADT (HR: 0.52; 95% CI: 0.35–0.79).2
The following post hoc analyses data are not included in the full ERLEADA® (apalutamide) Prescribing Information.
Post hoc exploratory analyses investigated PSA kinetics.4,5 After 3 months of Apa treatment, median OS was not reached in patients with a PSA response. In patients without a PSA response, median OS was 37.7 months.5 Most Apa + ADT-treated patients had undetectable PSA at 3 months. By 12 months, 64% of Apa-treated patients had undetectable PSA vs 23% of patients treated with placebo + ADT.5
Please see the full Prescribing Information for ERLEADA® (apalutamide) at www.erleadahcp.com.
- Chi KN, et al. N Engl J Med. 2019;381:13–24.
- Chi KN, et al. J Clin Oncol. 2021;39:2294–2303.
- ERLEADA® (apalutamide) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
- Chowdhury S, et al. Ann Oncol. 2023;34:477–485.
- Chi KN, et al. Presented at AUA; September 10–13, 2021; Las Vegas, Nevada.